

NEK11L Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP8070b**Specification****NEK11L Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q8NG66](#)**NEK11L Antibody (C-term) Blocking Peptide - Additional Information**

Gene ID 79858

Other Names

Serine/threonine-protein kinase Nek11,
Never in mitosis A-related kinase 11,
NimA-related protein kinase 11, NEK11 (http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=18593)
HGNC:18593

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP8070b](#) was selected from the C-term region of human NEK11L. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

NEK11L Antibody (C-term) Blocking Peptide - Protein Information**NEK11L Antibody (C-term) Blocking Peptide - Background**

NEK11 belongs to the NIMA family of kinases, which are involved in DNA replication and genotoxic stress responses (Noguchi et al., 2002 [PubMed 12154088]).[supplied by OMIM]

NEK11L Antibody (C-term) Blocking Peptide - References

Blume-Jensen P, et al. Nature 2001. 411: 355. Cantrell D, J. Cell Sci. 2001. 114: 1439. Jhian S Oncogene 2000. 19: 5590. Manning G, et al. Science 2002. 298: 1912. Moller, D, et al. Am. J. Physiol. 1994. 266: C351-C359. Robertson, S. et al. Trends Genet. 2000. 16: 368. Robinson D, et al. Oncogene 2000. 19: 5548. Van der Ven, P, et al. Hum. Molec. Genet. 1993. 2: 1889. Vanhaesebroeck, B, et al. Biochem. J. 2000. 346: 561. Van Weering D, et al. Recent Results Cancer Res. 1998. 154: 271.

Name NEK11 ([HGNC:18593](#))

Function

Protein kinase which plays an important role in the G2/M checkpoint response to DNA damage. Controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-mediated polyubiquitination and degradation.

Cellular Location

Nucleus. Nucleus, nucleolus. Note=Nuclear during interphase but moves to the polar microtubules during prometaphase and metaphase (PubMed:12154088). Accumulates in the nucleolus in G1/S-arrested cells (PubMed:15161910).

Tissue Location

Poorly expressed in cerebellum, trachea, lung, appendix, and uterus.

NEK11L Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)